TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25820754
Drug: Pegfilgrastim 100
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 100 µg/kg/cycle
Study: 25820754
Drug: Pegfilgrastim 120
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim 120 µg/kg/cycle
Study: 23448344
Drug: Prasugrel reloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel reloading (20 mg)
Study: 23448344
Drug: Clopidogrel reloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel reloading (300 mg)
Study: 20509027
Drug: High-dose pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pegylated interferon α‐2b (peginterferon α‐2b) 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance)
Study: 20509027
Drug: High-dose pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pegylated interferon α‐2b (peginterferon α‐2b)
Study: 20108776
Drug: Kurarinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kurarinol (600 mg glucose injection IV once a day for 1 month, followed by Kurarinol capsule orally three times a day for 2 months)
Study: 20108776
Drug: Silybin Meglumine
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybin Meglumine Tablets (used in control group, same method and dosage as treatment group)
Study: 15197149
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and concurrent NSAIDs use
Study: 15197149
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and aspirin taken concomitantly
Study: 7530738
Drug: T3Ag-stimulated anti-C100-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3Ag-stimulated anti-C100-3 antibody production
Study: 30971276
Drug: Caffeinated gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated gum (200 mg caffeine)
Study: 26169181
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mirabegron 50mg/day and solifenacin 10mg/day for 6 weeks
Study: 20934856
Drug: Calcium-fortified cereal-legume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified cereal-legume snack (laddoo) (500 mg of calcium carbonate)
Study: 20934856
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate alone (500 mg)
Study: 17121895
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches before operation
Study: 17121895
Drug: Nitroglycerin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin treatment for 3 days before chemotherapy using DCb
Study: 17121895
Drug: No nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nitroglycerin treatment
Study: 17121895
Drug: Nitroglycerin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin treatment
Study: 15578397
Drug: Intermittent rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent rifampin and pyrazinamide (RZ) therapy, given twice weekly for 2 months
Study: 9305416
Drug: Loxiglumide (CCK-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK-A receptor antagonist)
Study: 2691129
Drug: Perindopril with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril with beta-blocker
Study: 4150435
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets
Study: 23264396
Drug: Brand-name L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand-name L-thyroxine (Synthroid)
Study: 23264396
Drug: Generic L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic L-thyroxine (Sandoz)
Study: 21522070
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (Stay Alert™ gum, 85 mg caffeine)
Study: 16750456
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg and 40 mg
Study: 16750456
Drug: Esomeprazole (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (both doses)
Study: 15730653
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution for patients with middle and small burn area (Na(+) = 130 mmol/L)
Study: 15730653
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution for patients with large burn area
Study: 15730653
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline resuscitation for patients with large burn area (Na(+) = 174 mmol/L)
Study: 10930892
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) based triple therapy
Study: 10930892
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) based triple therapy
Study: 8965746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of L-thyroxine and 150 micrograms iodine
Study: 8965746
Drug: Mono-L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-L-thyroxine treatment (control group B)
Study: 24778046
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg for 6 weeks, starting at week 6 of gemcitabine therapy)
Study: 24778046
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg for 12 weeks, starting at week 1 of gemcitabine therapy)
Study: 11425411
Drug: abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab bolus and 24 h infusion
Study: 11425411
Drug: abciximab bolus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab bolus and 48 h infusion
Study: 9482293
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal capsular polysaccharide vaccine
Study: 2536896
Drug: Propranolol (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10, 20, 40, and 80 mg every eight hours for one day)
Study: 2536896
Drug: Propranolol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (oral dose)
Study: 30006792
Drug: TXT-PHE (interactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXT-PHE (interactive text conversations with Peer Health Educators, plus five‐times‐a‐day automated theory‐based messages, plus a weekly self‐monitoring text‐message assessment)
Study: 30006792
Drug: TXT-Auto (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXT-Auto (daily automated messages and weekly self‐monitoring assessment)
Study: 30006792
Drug: AO (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO (weekly self‐monitoring assessment only)
Study: 28545364
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily light exposure
Study: 28545364
Drug: Lower daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower daily light exposure
Study: 25921747
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (50 mg) daily for 24 weeks
Study: 23381973
Drug: Ruxolitinib (10-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10-100 mg single doses and 10 mg or 25 mg every 12 hours multiple doses)
Study: 21799145
Drug: Dialysate flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate flow rate of 800 ml/min
Study: 21799145
Drug: Dialysate flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate flow rate of 600 ml/min
Study: 19783805
Drug: Combined periodontal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined periodontal and triple therapy
Study: 12931769
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral sedation with diazepam and local anesthetic
Study: 9188928
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg once daily
Study: 1416574
Drug: Single 1-gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1-gram dose of ciprofloxacin (single-dose group; n = 40)
Study: 1416574
Drug: 1-gram dose
Normalized name: sulbactam
DrugBank: Sulbactam (DB09324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-gram dose of ciprofloxacin at admission and 24 hours later (2-dose group; n = 43)
Study: 1416574
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ciprofloxacin every 12 hours for 5 days (10-dose group; n = 35)
Study: 3889004
Drug: None (absence
Approvals — FDA: no, EMA: no, PMDA: no
Description: None (absence of antibiotic prophylaxis)
Study: 30588994
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene care, toothbrushing education, and fluoride varnish application once per week for 8 weeks
Study: 23988443
Drug: 0.05% oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray, 100 μg dose
Study: 23988443
Drug: Sham 'spray'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham 'spray' (untreated control)
Study: 24032184
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Kuijiening plaster + SASP)
Study: 24032184
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Kuijiening plaster, SASP, combined therapy)
Study: 20216301
Drug: ART interruption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART interruption (drug conservation)
Study: 14528481
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (expectant or medical treatment)
Study: 7555986
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) at 40 mg/kg/day, increased to 60 and 80 mg/kg/day if seizures persisted
Study: 1983701
Drug: Five anxiolytic
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five anxiolytic benzodiazepines taken nocte for 7 days
Study: 7028299
Drug: Aluminium phosphate-adsorbed
Normalized name: Aluminium phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium phosphate-adsorbed cholera vaccine
Study: 31290176
Drug: 20-G fine-needle
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20-G fine-needle biopsy (FNB)
Study: 28669488
Drug: Discharge Hyponatremia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge Hyponatremia (Na <135 meq/L)
Study: 23818295
Drug: Protocol based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol based therapy (antibiotic regimens for eradication of newly identified Pseudomonas)
Study: 23818295
Drug: Protocol based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol based therapy
Study: 21256809
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (10 million units flat dose subcutaneously 5 days per week for 4 weeks, then 10 million units flat dose subcutaneously 3 days per week for 12 months) - Group B
Study: 21256809
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (10 million units flat dose subcutaneously 5 days per week for 1 month, then 10 million units flat dose subcutaneously 3 days per week for 24 months) - Group C
Study: 14691389
Drug: Ethanol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.4 g/kg every 4 hr in 200 ml of orange juice)
Study: 11154618
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Ginkgo biloba extract LI 1370 three times daily for 12 weeks
Study: 9884858
Drug: remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Study: 1111453
Drug: Intravenous clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clindamycin phosphate
Study: 7031847
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trimipramine at night
Study: 22265034
Drug: Pre-emptive ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive ibuprofen (400 mg)
Study: 15837968
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Study: 15837968
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (subtotal nodal radiation for favorable risk or combined-modality therapy for unfavorable risk)
Study: 15837968
Drug: Combined-modality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality treatment (for unfavorable risk patients)
Study: 12495553
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba capsules (120 mg)
Study: 9872352
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benfotiamine and vitamins B6 and B12
Study: 7759675
Drug: Culturally sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally sensitive perspective to treatment outcome research
Study: 18046976
Drug: zofenopril 30-60
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zofenopril 30-60 mg once daily
Study: 18046976
Drug: atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50-100 mg once daily
Study: 11400817
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg recombinant vaccine intramuscularly (IM)
Study: 11400817
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg recombinant vaccine intradermally (ID)
Study: 8350215
Drug: High-dose steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroids and Elemental diet
Study: 16530757
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (viagra) 100 mg
Study: 10764172
Drug: Intrathecal 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.5 mg morphine (Group IT0.5)
Study: 10764172
Drug: Intrathecal 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.1 mg morphine (Group IT0.1)
Study: 10764172
Drug: Intravenous 10
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10 mg morphine (Group IV)
Study: 10764172
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia alone (Group C)
Study: 8844444
Drug: VX-366 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-366 (1, 7, 14 or 28 grams or approximately 14, 100, 200 or 400 mg/kg)
Study: 8844444
Drug: VX-366 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-366 (100 to 150 mg/kg)
Study: 6190318
Drug: simultaneous radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: simultaneous radio-chemotherapy
Study: 23558909
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT) with continuous monitoring of stroke volume variation (SVV) and stroke volume (SV) using FloTrac/Vigileo, receiving 1,589 ml of colloids during surgery.
Study: 23558909
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT) with continuous monitoring of stroke volume variation (SVV) and stroke volume (SV) using FloTrac/Vigileo, SVV decreased from 9.0 to 8.0 % during surgery.
Study: 23558909
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) receiving 927 ml of colloids during surgery.
Study: 23778198
Drug: Multicomponent cognitive
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent cognitive behavioral group intervention (8 weekly sessions + 1 booster session)
Study: 14700554
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement for 12 months
Study: 2964253
Drug: Amlodipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-10 mg daily, titrated at 2 weekly intervals for 8 weeks)
Study: 2964253
Drug: Amlodipine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (various doses)
Study: 23975134
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate tablets
Study: 12535040
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion anaesthesia (3 mg x kg‐1 induction, 20, 15 and 10 mg x kg‐1 x h‐1 maintenance)
Study: 12535040
Drug: Thiopenthal induction
Normalized name: thiopental Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopenthal induction (5 mg x kg‐1) followed by halothane maintenance (2-3%)
Study: 10377733
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy for chronic HBV hepatitis: 5 MU thrice weekly for 6 months
Study: 10377733
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy for chronic hepatitis C: protocols changed over time from 3 x 3 MU for 6 months to 3 x 3 MU for 12 months, including combination with ribavirin
Study: 9193433
Drug: Early ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ramipril (10 mg)
Study: 9193433
Drug: Delayed ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed ramipril (10 mg, day 14)
Study: 3959968
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg buprenorphine
Study: 3959968
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg buprenorphine
Study: 3959968
Drug: Urine assay
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine assay for opiate drugs
Study: 11279974
Drug: Histamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (0.1 to 1 ng, subcutaneous administration, twice a week for 12 weeks)
Study: 11279974
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous administration, twice a week for 12 weeks)
Study: 1578306
Drug: Daily corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily corticosteroid regimen
Study: 1578306
Drug: Daily corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily corticosteroid regimen (after switching to alternate-day therapy)
Study: 1578306
Drug: Alternate-day corticosteroid
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day corticosteroid therapy (continued from the outset)
Study: 2859648
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of histamine receptors with Fenistil plus Tagamet
Study: 27020487
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous ephedrine 10mg (Group E)
Study: 23702697
Drug: IVIG (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (1-2 g/kg, over 2 days)
Study: 22884767
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (starting dose, 4 U)
Study: 16044784
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) methods of comparison
Study: 16044784
Drug: Cognition-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognition-based medicine (CBM)
Study: 7043753
Drug: CMF +
Normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF + MER (immunotherapy with methanol extract residue of BCG)
Study: 29784470
Drug: MenACWY-TT (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-TT (single-dose at 15-18 months)
Study: 29784470
Drug: Routine childhood
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine childhood vaccines (PHiD-CV and DTPa-IPV/Hib)
Study: 29784470
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (MenACWY-TT and routine vaccines)
Study: 22903909
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy for 10 weeks
Study: 12088814
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam 0.1 mg/kg followed by 7% sevoflurane with 50% N(2)O
Study: 9569075
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate (i.m. MP) 120 mg 3-weekly